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Background/Aims
A limited number of studies are available regarding the long-term natural history of post-infectious irritable bowel syndrome (PI-IBS). 
We aimed to investigate the long-term clinical course of PI-IBS.
Methods
A prospective cohort study was conducted from a 2001 shigellosis outbreak in a Korean hospital with about 2000 employees. A 
cohort of 124 hospital employees who were infected by Shigella sonnei due to contaminated food in the cafeteria, and 105 sex- and 
age-matched, non-infected, controls were serially followed for their bowel symptoms by questionnaire surveys for 10 years.
Results
The Shigella-infected cohort showed significantly higher odds ratio for irritable bowel syndrome (IBS) at 1-year (11.90; 95% CI, 1.49-
95.58) and 3-year (3.93; 95% CI, 1.20-12.86) follow-up, compared to their controls. However, corresponding odds ratio for PI-IBS 
was not significantly increased at 5-year (1.88; 95% CI, 0.64-5.54) and 8-year (1.87; 95% CI, 0.62-5.19) follow-up. At 10-year follow-
up survey, the prevalence of IBS was similar for the Shigella-infected cohort and their controls (23.3% versus 19.7%, P = 0.703). Risk 
factors which were independently associated with PI-IBS among the Shigella-infected cohort included younger age, previous history of 
functional bowel disorder, and longer duration of diarrhea at baseline.
Conclusions
Patients who were infected by Shigella sonnei experienced significantly increased risk of IBS until 3 years after shigellosis, and modestly 
increased risk until 8 years, but showed similar risk of IBS with uninfected controls at 10 years post-infection. PI-IBS is quite a chronic 
disorder, and follows a long-term natural course.
(J Neurogastroenterol Motil 2016;22:490-496)
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Introduction  
Irritable bowel syndrome (IBS) is one of most common chronic 
gastrointestinal disorders, and is characterized by abdominal pain or 
discomfort associated with disturbed and altered bowel habit in the 
absence of organic disease.1 IBS is a common digestive disease, with 
a variable prevalence of 4-22% worldwide.2 Although it is not a life-
threatening disorder, IBS poses significant quality of life concerns 
and remains a substantial burden on the health care system.3
The pathophysiology of IBS is thought to be multifactorial, 
and possible mechanisms of IBS include altered bowel motility, 
visceral hypersensitivity, psychosocial distress, abnormal brain-gut 
interaction, enteric infection, gut-immune activation, low grade 
inflammation, intestinal permeability, and alterations in intestinal 
microflora.4-9
The role of enteric infection in the pathogenesis of IBS has 
been recognized since Chaudhary and Truelove10 first reported the 
association between infectious gastroenteritis and persistent gas-
trointestinal symptoms. While many enteric infections cause self-
limiting illness, 5-30% of people experience new gastrointestinal 
symptoms that persist after bacterial dysentery, despite clearance of 
the inciting pathogen.11 Additionally, approximately 10% of IBS 
patients reported that their symptoms began following a bout of 
infectious dysentery.12
Post-infectious IBS (PI-IBS) is defined as the acute onset of 
new IBS symptoms in an individual who has not previously met the 
criteria for IBS immediately following an acute illness characterized 
by 2 or more of the following: fever, vomiting, diarrhea, or positive 
bacterial stool culture.12
Although there have been many reports regarding PI-IBS 
associated with pathogens such as Shigella spp., pathogenic Esch-
erichia coli, Salmonella, Campylobacter jejuni, and Giardia duode-
nalis in the past 20 years,13-19 most of these reports address the short-
term clinical course of PI-IBS, and only few examined the long-
term course (≥ 5 years) of PI-IBS.20-23
We previously reported on the clinical course of PI-IBS in a 
homogenous cohort comprised of patients recovered from shigel-
losis.17,23,24 In the current study, we report on the collective results of 
a 10-year, long-term follow-up of our small, well-followed, homog-
enous cohort of patients that developed PI-IBS after shigellosis.
Materials and Methods  
Subjects
In December 2001, a shigellosis outbreak took place at Gangnam 
Severance Hospital (formerly “Youngdong Severance Hospital”) in 
Seoul, Korea, due to the consumption of contaminated food in the 
hospital employee cafeteria. The causative pathogen was Shigella 
sonnei, and a total of 181 patients were diagnosed and treated for 
shigellosis. All patients were medical personnel including physi-
cians, nurses, paramedics, and medical students. After termination 
of the shigellosis outbreak, we established a cohort of Shigella-ex-
posed patients who agreed to participate in serial follow-up surveys. 
Patients who were pregnant, those who had already symptoms of 
IBS before shigellosis, and who had a history of abdominal surgery 
or chronic organic gastrointestinal disorders were excluded. The 
initial Shigella-exposed cohort was comprised of 143 subjects.
To serve as a control population, we recruited healthy age- 
and sex-matched volunteers who were working for the hospital at 
the time of the shigellosis outbreak (they were not exposed to the 
contaminated food), and among them, subjects who already had 
symptoms of IBS before shigellosis was excluded from control co-
hort and followed separately as sporadic IBS subjects in subsequent 
analyses.
For the 10-year follow-up survey, we built a list of 124 sub-
jects in the Shigella-exposed cohort who were still working for the 
hospital, or those who were retired but contactable by phone calls. 
Among the control group, we were able to contact 105 subjects in 
the same manner.
Methods
Both the Shigella-exposed cohort and the control cohort were 
asked to participate in follow-up questionnaires at 1, 3, 5, 8, and 10 
years after recruitment. The initial 1-year and 3-year surveys ad-
dressed epidemiologic data, past medical and surgical history, infor-
mation regarding the presence of vomiting, fever, and duration of 
diarrhea during the acute illness, and information regarding current 
bowel symptoms according to the Rome II criteria.17,24 The follow-
up questionnaires at 5, 8, and 10 years after outbreak mainly ad-
dressed current bowel symptoms according to the Rome II criteria, 
as well as recent medical history of other gastrointestinal disorders, 
including incidence of additional enteric infection and/or abdominal 
surgery, which was exclusion criteria for subsequent analyses.23 The 
diagnosis of IBS and other functional bowel disorders (FBDs) was 
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made using the Rome II criteria, and other FBDs included func-
tional abdominal bloating, functional constipation, functional diar-
rhea, and unspecified FBDs
For the 10-year follow-up survey, investigators performed the 
survey questionnaire preferentially by face-to-face interview, and by 
telephone interview, if necessary. A small financial reward ($10) was 
given in acknowledgement of subjects’ participation in the study. 
Written informed consent was obtained from each subject before 
the survey, and the University of Yonsei Medical School Ethics 
Committee approved the study protocol (IRB approval number: 
3-2011-0242).
Statistical Methods
Cohort members and their controls were compared by inde-
pendent t test for continuous variables, and by Chi-square test or 
Fisher’s exact test for categorical variables. Logistic regression anal-
ysis was performed to calculate OR and 95% CI for prevalent IBS 
at each time interval or newly-developed IBS during a given time-
interval, after adjustment for sex and age. All statistical calculations 
were performed using the Statistical Package for the Social Sciences 
(SPSS, 18.0 Inc, Chicago, IL, USA). A P-value of less than 0.05 
was regarded as statistically significant.
Results  
Response Rate and General Characteristics
A total of 229 subjects (124 in the Shigella-exposed group, 
105 in the control group) were surveyed periodically for 10 years 
following the December 2001 shigellosis outbreak. Ten years post-
outbreak, the overall response rate was 70.7% (162/229), while the 
response rate of the Shigella-exposed group was 69.4%, which was 
not significantly different from the response rate (72.4%) of the 
control group (Table 1). The mean age of study subjects 10 years 
post-outbreak was 41.8 years for the Shigella-exposed group and 
39.6 years for the control group (P = 0.071). The female-to-male 
ratio was 2.8 for the Shigella-exposed group and 2.9 for the control 
group (P = 0.943).
Prevalence of Irritable Bowel Syndrome at Each 
Time Point
The prevalence of IBS after the shigellosis outbreak was ana-
lyzed at each time point after exclusion of subjects who had symp-
toms of IBS prior to the outbreak (Table 2).
The prevalence of IBS after 1 year was 13.1% in the Shigella-
exposed group and 1.1% in the control group. Thus, the risk of IBS 
Table 1. Survey Response Rate at Each Time Point
Survey time (yr)
Shigella-exposed group Control group
Planned subjects Responded subjects (response rate) Planned  subjects Responded subjects (response rate)
1st 143 101 (70.6%) 113 102 (90.3%)
3rd 124 95 (76.6%) 120 105 (87.5%)
5th 75 59 (78.7%) 78 60 (76.9%)
8th 133 71 (53.4%) 105 65 (61.9%)
10th 124 86 (69.4%) 105 76 (72.4%)
Table 2. Prevalence of Newly-developed Irritable Bowel Syndrome After Shigellosis Outbreak at Each Time Point
Survey time (yr)
Shigella-exposed group Control group Adjusted OR
(95% CI)Total No. No. of IBS Total No. No. of IBS
1st 87 12 (13.8%) 89 1 (1.1%) 11.9 (1.49-95.58)
3rd 87 13 (14.9%) 89 4 (4.5%) 3.93 (1.20-12.86)
5th 53 11 (20.8%) 49 6 (12.2%) 1.88 (0.64-5.54)
8th 71 11 (15.4%) 65 6 (9.2%) 1.87 (0.62-5.19)
10th 86 20 (23.3%) 76 15 (19.7%) 1.61 (0.70-3.69)
IBS, irritable bowel syndrome.
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in the Shigella-exposed cohort was significantly higher than that 
of the control cohort at the 1-year follow-up survey (adjusted OR, 
11.90). The prevalence of IBS at the 3-year follow-up survey was 
also significantly higher in the Shigella-exposed group than the con-
trol group (adjusted OR, 3.93). However, at the 5-year and 8-year 
follow-up surveys, the prevalence of IBS in the Shigella-exposed 
cohort was modestly increased but not statistically significant com-
pared to the control cohort. The 10-year follow-up survey showed 
similar IBS prevalence in both groups (23.3% for Shigella-exposed 
group, 19.7% for control group; P = 0.703).
Incidence of Irritable Bowel Syndrome During Each 
Time Interval
The incident of IBS during each time interval was defined 
as newly-developed IBS among subjects who did not report IBS 
symptoms in the previous survey (Table 3). The incidence of newly-
developed IBS was significantly higher in the Shigella-exposed 
group than the control group during the first year post-outbreak. 
However, no significant differences were demonstrated between the 
2 groups at subsequent follow-up intervals.
Irritable Bowel Syndrome Prognosis
We were able to follow-up 12 patients who developed PI-IBS 
among the Shigella-exposed cohort up to 10 years after the shigel-
losis outbreak. Also, we could follow up the natural history of 14 
sporadic IBS (not “post-infectious”) patients among the control co-
hort who were initially recruited at the time of outbreak,23 and were 
excluded from the subsequent analysis of newly-developed IBS 
because they already had symptoms of IBS prior to the outbreak.
The figure represents the 10-year natural history of PI-IBS 
patients (Figure A) and sporadic IBS patients (Figure B). About 
half of the PI-IBS patients showed remission of IBS symptom after 
5 years. However, approximately 25-30% of PI-IBS patients had 
persistent IBS symptoms even after 8 to 10 years. The natural his-
Table 3. Incidence of Newly-developed Irritable Bowel Syndrome During Each Time Interval
Time interval (yr)
Shigella-exposed group Control group Adjusted OR
(95% CI)Total No. No. of incident IBS Total No. No. of incident IBS
0-1 87 12 (13.8%) 89 1 (1.1%) 11.9 (1.49-95.58)
1-3 71 4 (5.6%) 84 3 (3.6%) 1.61 (0.35-7.46)
3-5 46 6 (13.0%) 46 3 (6.5%) 2.15 (0.50-9.18)
5-8 71 4 (5.6%) 65 3 (4.6%) 1.23 (0.26-5.73)
8-10 71 11 (15.5%) 67 10 (14.9%) 1.04 (0.47-2.28)
IBS, irritable bowel syndrome.
Figure. Natural history of post-infectious irritable bowel syndrome (PI-IBS) after shigellosis (A), and sporadic IBS in control subjects (B) over 10 
years. Twelve PI-IBS patients and 14 sporadic IBS patients were followed for 10 years. Approximately half the patients recovered from IBS after 5 
years, but several patients had persistent IBS symptoms for the duration of the study. The natural history of PI-IBS and sporadic IBS seem to be 
quite similar.
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tory of the 14 sporadic IBS (not-related to shigellosis) patients was 
quite similar to the prognosis of PI-IBS patients.
Risk Factors Associated with Post-infectious Irritable 
Bowel Syndrome Development
We analyzed the risk factors which were associated with the 
ever-developed PI-IBS in the Shigella-exposed subjects. Younger 
age, previous history of FBDs other than IBS at baseline, and dura-
tion of diarrhea in initial dysentery were significantly associated with 
PI-IBS development during the follow-up over 10 years (Table 4).
Discussion  
Since Chaudhary and Truelove10 first reported the concept of 
PI-IBS in 1962, there has been a substantial amount of epidemio-
logic data published regarding the association between PI-IBS 
and various pathogens, including bacterial, protozoal, and viral 
pathogens. Several studies have established the causative pathogens 
of PI-IBS, including Shigella spp.,16,23 pathogenic E. coli,22 Salmo-
nella spp.,13,18 C. jejuni,15 G. duodenali,19 Trichinella britovi,25 noro-
virus,26 or combinations of the preceding pathogens.14,22
The reported incidence of PI-IBS varies from about 5-30%,11 
and PI-IBS is now a well-recognized consequence of acute infec-
tious gastroenteritis. There is little doubt that bouts of infectious 
enteritis may cause some patients to suffer from chronic IBS symp-
toms, and this fact was also validated by the results of our study. 
However, little data is available for long-term natural history of PI-
IBS.
As far as we know, there have been only 3 studies that have fol-
lowed participants with PI-IBS for more than 5 years.20-22 Among 
these relatively long-term reports, one is a 6-year follow-up study 
from a British cohort,20 another is a 5-year follow-up study from a 
Swedish cohort,21 and the other is an 8-year follow-up study from 
a Canadian cohort.22 However, our study followed Korean patients 
for 10 years, and as such is the longest follow-up study concerning 
PI-IBS. Moreover, our cohort consisted of a homogenous group 
of patients who were infected with a single pathogenic strain (S. 
sonnei) from the same contamination source. The 8-year follow-
up study with thousands of participants from Walkerton, Canada22 
could provide the most useful data due to the sample size and 
consequential statistical power, while our study is limited in its small 
sample size. However, in the Walkerton cohort, the infecting patho-
gens were variable combinations of E. coli 0157:H7, C. jejuni, and 
other pathogens, ultimately resulting in increased heterogeneity of 
the study population.
Our current study might improve our understanding of long-
term prognosis of PI-IBS. Approximately half of the patients in 
our study recovered 5 years post-infection, whereas 25-33% still 
suffered from PI-IBS even 8-10 years post-infection. These results 
are generally consistent with those of previous long-term studies.20-22 
Additionally, we found that the long-term natural course of PI-
IBS was similar to that of sporadic IBS in our cohort. Although we 
found a slightly higher incidence of IBS in the Shigella-exposed 
group than the control group at 5 and 8 years post-outbreak, the 
differences were not statistically significant. These findings are in 
contrast with those of the Walkerton study, where the difference 
in IBS prevalence was still significantly higher after 8 years in the 
infected group compared to the control group (OR, 3.12; 95% 
CI, 1.99-5.04).22 This discrepancy might have resulted from the 
difference in sample size, infecting pathogens, or population char-
acteristics. With this in mind, the non-significant difference in IBS 
prevalence between the infected and control groups in our study 
after 5 years does not indicate that acute infectious gastroenteritis 
did not affect the PI-IBS patients for longer than 5 years. The issue 
of how long the difference in the prevalence of IBS lasts between 
infected and control group cannot be clearly concluded yet, and we 
believe that this issue might be also influenced by regional socio-
environmental factors of the each cohort.
Table 4. Analysis of Risk Factors Associated with Development of 
Post-infectious Irritable Bowel Syndrome in Shigella-exposed Group 
During 10-year Follow-up
Baseline characteristics OR (95% CI) 
Age (yr)
    < 40 1.00
    ≥ 40 0.94 (0.89-0.99)
Sex 
    Male 1.00
    Female 2.00 (0.75-5.54)
History of other FBDa
    No 1.00
    Yes 5.10 (1.2-21.1)
Duration of diarrhea
    No 1.00
    Yes 1.27 (1.01-1.60)
Vomiting
    No 1.00
    Yes 0.58 (0.14-2.39)
Fever
    No 1.00
    Yes 1.57 (0.68-3.64)
aFunctional bowel disorders (FBDs) other than irritable bowel syndrome (IBS), 
including functional abdominal bloating, functional constipation, functional 
diarrhea, and unspecified FBDs by Rome II criteria.
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The risk of newly-developing PI-IBS in the Shigella-exposed 
group is significantly higher only during the first year post-infection, 
whereupon the development of new sporadic IBS was the same in 
the 2 groups. Because PI-IBS is a chronic disorder, the difference 
in the prevalence of IBS between the 2 groups can persist for sev-
eral years post-infection. After 10 years, however, IBS prevalence in 
the infected group decreased to nearly the same level as that of the 
control group. This is likely because the PI-IBS patients recovered 
gradually while patients in the control group developed new spo-
radic IBS.
The mechanisms that underlie PI-IBS remain largely unclear, 
but several mechanisms have been proposed including immune 
activation, chronic low grade inflammation, enterochromaffin cell 
hyperplasia, and alteration of epithelial permeability and neuromus-
cular function.12,27 Additionally, functional gastrointestinal disorders 
following acute infectious gastroenteritis not only include PI-IBS, 
but also post-infectious dyspepsia.18,28,29 The final symptom com-
plex depends on the interaction between local mucosal injury and 
central factors including adverse life events, personality, and external 
stressors. Additionally, local injury is often more highly influenced 
by the nature of the infectious agent. Rotavirus and Giardia infec-
tion mainly involve the upper gastrointestinal tract, and thus may 
predominantly predispose patients to dyspepsia, whereas Shigella 
infection is confined to the left colon and exclusively predisposes 
patients to IBS. Salmonella or Campylobacter infections cause ileitis 
and colitis, equally predisposing patients to both dyspepsia and IBS. 
Because our cohort was comprised of patients exclusively infected 
by S. sonnei, the absence of post-infectious dyspepsia was expected. 
Conversely, post-infectious dyspepsia was common in the Walker-
ton cohort.28
Risk factors for PI-IBS in the results of our study are consis-
tent with those from previously published studies, which suggest 
that duration and severity of initial illness, toxicity of infecting 
pathogens, female sex, younger age, previous history of functional 
gastrointestinal disorder, and psychosocial factors are risk factors 
for developing PI-IBS. In our study, younger age, previous history 
of FBD, and duration of diarrhea showed statistically significant 
associations with PI-IBS development, whereas female sex and 
fever showed increased but statistically nonsignificant odds ratios, 
possibly due to the small number of study subjects. Additionally, we 
found no association between vomiting and PI-IBS, which may be 
explained by the nature of Shigella (which primarily affects the left 
colon).
We followed our cohort with regular surveys on bowel symp-
toms 1, 3, 5, 8, and 10 years after outbreak. During the course of 
the surveys, the response rate and final number of participants were 
lowest at the 5-year survey, and gradually rose to about 70% at the 
10-year survey. The small number of participants at the time of the 
5-year survey might be due to the exclusion of all subjects who had 
been excluded from 1-year and 3-year analysis. The response rate 
of the 10-year survey was relatively higher than previous surveys, 
because we tried multiple contacts using both face-to-face interview 
and telephone interview.
The prevalence of IBS increased between 8-10 years post-
outbreak in both the infected and control groups. The cumulative 
incidence of IBS between 8 to 10 years post-outbreak was 15.5% 
in the infected group and 14.9% in the control group, which are 
values quite high compared with other interval periods. We cannot 
definitively explain this increased IBS rates, but we posit that hospi-
tal workers may have been exposed to a stressful work environment 
during that period. Indeed, a series of hospital qualifying programs 
(Joint Commission International accreditation and Korean Institute 
for Healthcare accreditation) continued to proceed at the time of 
the 10th year survey, and the workload of many hospital workers 
was heavier than usual. We presume that stressful workload might 
be associated with increase of IBS at the 10th year survey.
The current study has also several limitations. Firstly, the rela-
tively small size of cohorts may decrease the statistical reliability. 
Secondly, we tried to exclude new PI-IBS due to additional enteric 
infection after the initial bout of shigellosis, by surveying the history 
of additional enteric infection between the periods, however there 
might be some recall bias. Thirdly, the diagnosis of IBS was made 
by symptoms at only each time points of the surveys, and was not 
continuously monitored throughout the 10 years, and so, time de-
pendent Cox regression analysis could not be applied to clarify the 
prognosis of PI-IBS.
In conclusion, the relative risk of PI-IBS was significantly 
higher in the infected group compared to the control group up to 
3 years after shigellosis, but gradually decreased thereafter. The 
natural history of PI-IBS and sporadic IBS seem to be similar, and 
in our study approximately half of patients in each group recovered 
after 5 years, whereas symptoms persisted for 10 years in about one 
third of patients. The duration of diarrhea as an index of severity of 
initial illness, previous history of FBD, and younger age were risk 
factors for PI-IBS.
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